The growth of the cannabis space has given investors plenty of opportunities for major returns. With 2017 being a particularly establishing year for the industry, many investors have celebrated the developments of the industry as a whole.
With 2017 coming to an end, here the Investing News Network (INN) takes a closer look at the top cannabis stocks when it comes to gains. The figures collected for this article were taken from Google Finance, from the start of the trading year or a particular company’s public launch until market closure on Dec. 14.
Read below to find out about the top gaining stocks in each Canadian exchange and a collection of honorable mentions.
Cannabis experts and market analysts offered valuable insight and 2020 forecasts for the quickly evolving cannabis sector
Read our new report on the MJBizConINT'L Conference
Canopy Growth (TSX:WEED)
Canopy is still the largest cannabis producer in Canada and arguably the biggest cannabis company right now. This year they provided steady developments with new deals including an investment from Constellation Brands (NYSE:STZ), the alcohol producer behind the Corona beer. This partnership will begin working on potential new cannabis-infused drinks.
During 2017 Canopy’s market cap vacillated between one and two billion. Over a year-to-date period, the company’s share price saw a 113.68 percent growth.
The Hydropothecary Company (TSXV:THCX)
This company started publicly trading on the TSX Venture exchange in March. During the year the Hydropothecary faced some issues with a product recall, due to products testing positive for small amounts of myclobutanil, a pesticide, in them.
“As a result of the investigation, the Company has determined that the voluntary pesticide management systems implemented in September 2016 have proven effective and that the contamination occurred during an earlier period,” the company told investors on June 05, after completing an investigation into its products.
Despite the recall, the company was able to put together a solid year of business, with new sale licenses and expansion in its future. Over a year-to-date period, the company increased its share price 473.53 percent.
Global Hemp Group (CSE:GHG; OTC:GBHPF)
Instead of a more traditional grower or medical supplies, Global Hemp is an option for investors with an eye on the industrial hemp business. According to the company, they are focused on acquiring or joining up with companies in the industrial hemp market.
Twice in the last few months, the company issued separate statements denying any awareness as to why their share price had seen the increases it had recently. As it’s allowed with the CSE, with the proper disclosure, Global Hemp holds assets in the US landscape with a venture alongside with a company called Space Cowboys, a hemp derived cannabinoid producer in Colorado.
Over a year-to-date period, the company has seen a rise to its stock worth 466.67 percent.
This company’s growth strategy includes the development of over-the-counter and pharmaceutical drugs based in cannabinoid therapies.
Lately, the company has turned its attention to the developing blockchain market. In December the company announced it had initiated Phase 1 of implementing cryptocurrency through BitPay. “In Phase 2 of the implementation, which takes place in the first quarter of 2018, we anticipate cryptocurrency acceptance across all of Isodiol’s family of brands,” Marcos Agramont, CEO of Isodiol said.
Year-to-date, the company saw its share price rose 1116.67 percent.
- Matica Enterprises (CSE:MMJ)
Matica has invested heavily in two ACMPR applicants for cannabis licenses. The company expects these to develop and produce gains moving forward. In September the company announced its intentions to become the new majority owner of a cannabis producer in southwestern Ontario, currently applying for Canadian cannabis license.
“This new project will give us the size we need to be competitive in the medical and recreational markets,” Boris Ziger, CEO of Matica Enterprises CEO said.
This year, Matica’s stock has seen a 1400 percent increase.
MYM is focused on the acquisition, whether it’s new sale and production licenses or other assets complimentary of the cannabis industry.
The company has ventured into the Australian market, a recent favorite of Canadian LPs for exports and new partnerships. This year MYM detailed their plans to build a 1.5 million-square-foot cannabis production facility consisting of fifteen 100,000-square-foot greenhouses. This expansion is being done in partnership with the municipality of Weedon, Quebec.
Since January 1, MYM Nutraceuticals has seen a 5045.45 percent increase in its share value.
This year WeedMD announced major new expansion plans for its future development in the industry. A recent purchase agreement with Perfect Pick Farms gave the company new facilities to develop for the production of cannabis.
These new facilities account for 14 acres of greenhouse facilities, that according to WeedMD are “ready for rapid retrofit for cannabis cultivation.” In a business landscape where expansion is crucial, this acquisition is key for WeedMD
In early December the company announced it had officially been added to the Horizons Marijuana Life Sciences Exchange-Traded Fund (ETF) (TSX:HMMJ). The ETF gives investors exposure to some of the biggest players in the cannabis space.
This year the company’s share price has increased 594.29 percent
Tetra Bio-Pharma is focused on the development of cannabinoid (CBD) clinical stage products. Their pipeline of products includes candidates in pain management and recovery from cancer treatment side effects.
The company continued a steady path forward in terms of developments throughout the year. In November, the company gave shareholders an update on its intentions for a new drug application with the US Food and Drug Administration on Dronabinol XL AdVersa. The company is co-developing this treatment alongside IntelGenX (TSXV:IGX; OTCQX:IGXT).
In 2017 Tetra Bio-Pharma has seen a 1357.14 percent rise to its share price.
Supreme is a Canadian LP with growing options thanks to its subsidiary 7ACRES. This year the company obtained its official license to sell cannabis products. Supreme also graduated from listing on the Canadian Securities Exchange to the TSX Venture exchange in 2017.
The company completed two substantial sales this year to Aurora Cannabis and Emerald Health Botanicals, a subsidiary of Emerald Health Therapeutics (TSXV:EMH). Over a year-to-date period, Supreme has seen a whopping 3780 percent growth in its share price.
- MedReleaf (TSX:LEAF)
MedReleaf started publicly trading on the TSX on June 7 of this year. Despite the anticipation from experts, the company stumbled into a less than lackluster IPO. After initially expecting an asking price of $9.50 per share, it closed its first public day at $7.40. The overvaluation hit at a larger concern in the industry for cannabis stocks, but regardless of the launch, the company ended up regrouping and going over its initial asking price. On Nov. 13 the company closed at a year high of $18.25 per share.
Since its launch on the TSX, MedReleaf has seen a 116.22 percent increase to its share price.
Aphria continued its growth despite a back and forth with the TMX Group on its options when it comes to owning cannabis assets or holding interests in the US while listed in Canada. Nonetheless, Aphria delivered one of the blockbuster deals of the year announcing they are set to become a leading supplier to Shoppers Drug Mart, through their online shop. Other producers have signed deals with other pharmacies, but this one represents two of the biggest players in the medical cannabis and pharmacy game.
Over a year-to-date period, Aphria has seen a 127.36 percent rise to its stock price.
Aurora Cannabis made sure 2017 was a year of expansion for them. The promise of their Aurora Sky facility’s production is still present in the eyes of new investors. This year they pursued new acquisitions including one with Larssen, a greenhouse engineering, and design consultancy company involved in projects with other LPs. Thanks to this acquisition Aurora will now expect to see new partnerships with any producer working with Larssen.
Throughout the year, Aurora enjoyed a 160.07 percent growth to its share price.
Do you feel a company you keep an eye on got left out of this list? Let us know about them in the comments and make their case to fellow investors.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Editorial Disclosure: Isodiol International, MYM Nutraceuticals, Supreme Pharmaceuticals and WeedMD are clients of the Investing News Network. This article is not paid-for content.